Independent risk factors evaluation for overall survival and cancer-specific survival in thyroid cancer patients with bone metastasis: A study for construction and validation of the predictive nomogram

Yuexin Tong, MD\textsuperscript{a}, Zhangheng Huang, MD\textsuperscript{a}, Chuan Hu, MD\textsuperscript{a,b}, Changxing Chi, MD\textsuperscript{c}, Meng Lv, MD\textsuperscript{d}, Pengfei Li\textsuperscript{a}, Chengliang Zhao, PhD\textsuperscript{a,*}, Youxin Song, PhD\textsuperscript{a,*}

Abstract
Bone is a frequent site for the occurrence of metastasis of thyroid cancer (TC). TC with bone metastasis (TCBM) is associated with skeletal-related events (SREs), with poor prognosis and low overall survival (OS). Therefore, it is necessary to develop a predictive nomogram for prognostic evaluation. This study aimed to construct an effective nomogram for predicting the OS and cancer-specific survival (CSS) of TC patients with BM. Those TC patients with newly diagnosed BM were retrospectively examined over a period of 6 years from 2010 to 2016 using data from the Surveillance, Epidemiology and End Results (SEER) database. Demographics and clinicopathological data were collected for further analysis. Patients were randomly allocated into training and validation cohorts with a ratio of \( \sim 7:3 \). OS and CSS were retrieved as research endpoints. Univariate and multivariate Cox regression analyses were performed for identifying independent predictors. Overall, 242 patients were enrolled in this study. Age, histologic grade, histological subtype, tumor size, radiotherapy, liver metastatic status, and lung metastatic status were determined as the independent prognostic factors for predicting the OS and CSS in TCBM patients. Based on the results, visual nomograms were separately developed and validated for predicting 1-, 2-, and 3-year OS and CSS in TCBM patients on the ground of above results. The calibration, receiver operating characteristic (ROC) curve and decision curve analysis (DCA) also demonstrated the reliability and accuracy of the clinical prediction model. Our predictive model is expected to be a personalized and easily applicable tool for evaluating the prognosis of TCBM patients, and may contribute toward making an accurate judgment in clinical practice.

Abbreviations: ATC = anaplastic thyroid cancer, AUC = area under the curve, BM = bone metastasis, CI = confidence interval, C-index = Harrell’s concordance index, CSS = cancer-specific survival, DCA = decision curve analysis, DM = distant metastasis, FTC = follicular thyroid carcinoma, HR = hazard ratios, MTC = medullary thyroid carcinoma, OS = overall survival, PTC = papillary thyroid cancer, ROC = receiver operating characteristic, SEER = Surveillance, Epidemiology and End Results, SRE = skeletal-related event, TC = thyroid cancer, TCBM = thyroid cancer with bone metastasis, TCDM = thyroid cancer with distant metastasis.

Keywords: cancer-specific survival, nomogram, overall survival, prognosis, SEER, thyroid cancer with bone metastasis
1. Introduction
According to the 2019 Cancer statistic report, thyroid cancer (TC) accounts for ~90% of all endocrine malignancies. TC is usually associated with a favorable prognosis, with a 10-year survival rate over 80%. This is predominantly attributed to the biological characteristics of the tumor and effective medical interventions. However, thyroid cancer with distant metastasis (TCDM) has a less favorable prognosis. Many risk stratification systems have classified TCDM as a high-risk group. Among various metastatic sites, See Anna et al. reported that bone is the most common site for distant metastases in TC (36.8%). A relevant research showed that the 10-year survival rate even dropped to 14% for patients older than 40 years having TCBM. In addition, the quality of life is severely affected for TCBM patients. One study showed that 78% of TCBM patients had at least one skeleton-related event (SRE) during a median follow-up period, and 49% had multiple SREs during a 5-year follow-up period, with significantly increased mortality compared to patients with bone metastases (BM). Therefore, the survival prognostic evaluation for TCBM patients is an important topic in the field of thyroid malignancy research.

The UICC/AJCC TNM classification and staging system is generally considered as a credible tool for evaluating the prognosis of malignancies in clinical diagnosis and treatment. TC is no exception. However, the TNM staging system does not sufficiently cover cancer the biological characteristics, treatment information of the tumor and specifically predict the OS for TCBM patients. During the past decades, numerous studies focusing on identifying prognosis-related variables of TCBM, including histological type, SREs, serum thyroglobulin (Tg), hypercalcemia, surgical resection of primary thyroid lesions, stereotactic radiotherapy, were conducted. However, to the best of our knowledge, there have been no studies focusing on the development of a predictive model for the overall survival (OS) and cancer-specific survival (CSS) in TCBM patients. In other words, the specific contribution of demographics, clinicopathological features and treatment methods in the survival rate of TCBM patients has not elucidated clearly. For this reason, our study aimed at constructing and validating a nomogram to predict the 1-, 2-, and 3-year OS and CSS for TCBM patients.

2. Materials and methods
2.1. Patients
This retrospective study was conducted using the SEER*Stat software version 8.3.5 to identify patients diagnosed as TCBM from the SEER program financed by the National Cancer Institute, and extract their data. The SEER database is the largest nationally representative cancer database consisting of 18 population-based cancer registries with nearly 30% of the US population. There was no requirement for the ratification of the ethics committee clearance and patient agreement and consent as no specific personal information was publicly available. As the information about site-specific metastasis was available from 2010 onwards, we limited our analysis between 2010 and 2016. Patients were excluded if a definite diagnosis was made based on necropsy findings or death certificate and detailed information was unavailable. Patients whose TC was not the first primary malignant tumor were also excluded. A total of 242 cases were found eligible for the study.

2.2. Data elements
The demographic, clinicopathological, and systematic treatment data of all included patients were extracted. A total of 15 variables, including age, race, sex, histological subtype, grade, laterality, tumor size, T stage, N stage, surgery, chemotherapy, radiotherapy, brain metastasis, liver metastasis, and lung metastasis were evaluated. Furthermore, information on other rare metastatic sites was extracted for this study. The histological subtype was classified into four categories with the following ICD-O-3 codes: 8340. 8341.8342.8344.8260—papillary thyroid cancer (PTC), 8330.8331.8335—follicular thyroid carcinoma (FTC); 8020.8021.8030.8032—anaplastic thyroid cancer (ATC); 8510. Medullary thyroid carcinoma (MTC). All cases were staged according to the 7th AJCC TNM classification.

2.3. Statistical analysis
Of the total 242 eligible TCBM patients, 170 were randomly allocated to the training cohort and the remaining 72 patients were allocated to the validation cohort to construct and validate the nomogram. All the demographic and clinicopathological variables were tested between two cohorts using Chi-squared ($\chi^2$) test. OS and CSS were designated as the two endpoints for this study. OS and CSS are defined as the period of time from the initial definitive diagnosis till death or till the day of the final clinical follow-up with the reason for death being attributed to all causes and TCBM, respectively. The age of the patients and tumor size of patients were compartmentalized using the X-tile program.

The establishment and validation of the nomogram was initiated with an univariate Cox regression analysis to study the correlation between each prognostic variable and OS & CSS, individually. Following that, variables with a $P$-value below .05 from the univariate analysis we univariate analysis were subjected to a multivariate Cox regression analysis. The variables with a final $P$-value below .05 were designated as independent prognostic factors. The above steps were performed using the Cox proportional hazards regression model. Additionally, Hazard ratios (HRs) and 95% confidence intervals (CIs) were also reported for each prognostic factor. Finally, based on the identified independent prognostic factors nomograms were established separately for the 1-, 2-, and 3-year OS and CSS via the RMS package in R software. The ROC curve was drawn, and the area under the curve (AUC) was used to represent the differentiation of the nomogram. A model was considered well-functioning if the AUC was between 0.5 and 1. On the whole, with an AUC > 0.75, is the model considered to have excellent performance in measuring separability. Calibration curves and DCA were also used to evaluate the accuracy of the nomogram, and $P < .05$ was considered statistically significant.

3. Results
3.1. Population information
All included TC patients were confirmed to have BM at initial diagnosis, with the bone being the only metastatic site or as a component of multiple organ metastasis. Table 1 shows the demographic and clinicopathological variables of all patients. The optimal cutoff value of age was identified as 58 years for OS and 59 years for CSS. The patients were divided into two groups to facilitate data processing (20–58 years and 59–90 years).
Analysis of the demographic data revealed that 112 patients (46.28%) were male and the remaining 130 (53.72%) were female. As for the race of the enrolled patients, majorities were White (n=170 [70.25%]). Of the various histological subtype, PTC (n=122 [50.41%]) was the most common subtype, followed by follicular thyroid cancer (n=61 [25.21%]), ATC (n=31 [12.81%]), and medullary carcinoma (n=28 [11.57%]). The most common T and N stages T3–4, respectively (32.3%) and N0 (55.37%). Some patients, besides having bone involvement, also had accompanying distant metastases to other sites. Of
them, 92 patients (38.02%) had lung metastases, 27 (11.46%) had liver metastases, and 12 (4.96%) had brain metastases. In addition, the data highlighted that surgery was the most widely accepted mode of treatment by the patients (80.17%), while chemotherapy and radiotherapy were given in a few cases (n = 42 [17.36%] and n = 168 [69.42%], respectively).

### 3.2. Prognostic factors of OS and CSS

Univariate and multivariate Cox analyses were performed to explore independent prognostic factors in the training cohort. The results for OS are shown in Table 2. Statistical evaluation revealed age (P = .001), grade (P = .009), combined liver metastasis (P = .001), histological subtype (P = .003) and radio-

| Table 2                                                                 | Univariate analysis | Multivariate analysis |
|------------------------------------------------------------------------|---------------------|-----------------------|
| **Characteristics**                                                     | HR (95% CI)         | P                     | HR (95% CI)         | P     |
| **Univariate analysis**                                                |                     |                       |                     |       |
| **Age**                                                                | Reference           | .001                  | Reference           |       |
| 20–58                                                                  | 2.484 (1.448–4.26)  | .001                  | 2.468 (1.415–4.304) | .001  |
| 59–90                                                                  |                     |                       |                     |       |
| **Race**                                                               |                     |                       |                     |       |
| Black                                                                  | Reference           | .245                  | .912                | .068  |
| Other                                                                  | 0.598 (0.252–1.422) | .798                  |                     |       |
| White                                                                  | 1.085 (0.581–2.028) | .166                  |                     |       |
| **Sex**                                                                | Reference           | .116                  |                     |       |
| Female                                                                 | 1.43 (0.915–2.234)  |                       |                     |       |
| Male                                                                   |                     |                       |                     |       |
| **Histological subtype**                                               |                     |                       |                     |       |
| Papillary                                                              | Reference           | .303                  | .891                |       |
| Follicular                                                             | 0.714 (0.376–1.355) | .303                  | 0.544 (0.284–1.045) | .068  |
| Anaplastic                                                             | 17.279 (8.689–34.363)| <.001                 | 3.93 (1.577–9.794)  | .003  |
| Medullary                                                              | 2.397 (1.116–5.147) | .025                  | 0.953 (0.405–2.241) | .912  |
| **Grade**                                                              | Reference           | .59                   |                     |       |
| Low (I, II)                                                            | 0.516 (0.047–5.702) | .826                  |                     |       |
| High (III, IV)                                                        | 0.479 (0.324–0.700) | <.001                 | 3.039 (1.312–7.038) | .009  |
| Unknown                                                                | 3.155 (2.274–4.378) | <.001                 | 0.841 (0.424–1.669) | .621  |
| **Laterality**                                                         | Reference           | .661                  |                     |       |
| Bilateral                                                              | 1.36 (1.13–3.4)     | .17                   |                     |       |
| Left—origin of primary                                                | 0.516 (0.047–5.702) | .59                   |                     |       |
| Not a paired site                                                      | 0.801 (0.111–5.797) | .826                  |                     |       |
| Right—origin of primary                                               | 1.664 (0.172–16.132)| .661                  |                     |       |
| **T stage**                                                            | Reference           | .017                  |                     |       |
| T1–2                                                                  | 1.96 (1.13–3.4)     | .017                  |                     |       |
| T3–4                                                                  |                     |                       |                     |       |
| **N stage**                                                            | Reference           | .001                  |                     |       |
| N0                                                                    | 2.316 (1.467–3.656) | <.001                 |                     |       |
| N1                                                                    |                     |                       |                     |       |
| **Radiotherapy**                                                       | Reference           | .001                  | Reference           | .001  |
| No                                                                    | 3.070 (0.195–0.483) | <.001                 | 0.407 (0.241–0.688) |       |
| Yes                                                                   |                     |                       |                     |       |
| Surgery                                                                | Reference           | .001                  | Reference           |       |
| No/unknown                                                             | 0.205 (0.125–0.334) | <.001                 |                     |       |
| Yes                                                                   | 4.912 (2.949–8.182) | <.001                 |                     |       |
| Chemotherapy                                                           | Reference           | .001                  |                     |       |
| No/unknown                                                             |                     |                       |                     |       |
| Yes                                                                   | 4.912 (2.949–8.182) | <.001                 |                     |       |
| Brain metastasis                                                       | Reference           | .344                  |                     |       |
| No                                                                    | 1.975 (0.483–8.079) | .344                  |                     |       |
| Unknown                                                                | 1.177 (0.429–3.229) | .752                  |                     |       |
| Liver metastasis                                                       | Reference           | .977                  | 2 (0.268–14.961)    | .499  |
| No                                                                    | 0.971 (0.134–7.035) | .977                  |                     |       |
| Yes                                                                   | 4.120 (2.349–7.220) | <.001                 | 4.986 (2.612–9.517) | <.001 |
| **Tumor size**                                                         | Reference           | .255                  |                     |       |
| 3–80                                                                  | 2.709 (1.578–4.882) | <.001                 |                     |       |
| 81–160                                                                 |                     |                       |                     |       |
therapy ($P = .001$) to be the independent risk factors. An identical method which was used to conduct for CSS identified age ($P = .006$), grade ($P = .008$), tumor size ($P = .006$), combined liver metastasis ($P = .001$), combined lung metastasis ($P = .007$), histological subtype ($P = .002$), and radiotherapy ($P = .017$) as the independent risk factors, as shown in Table 3.

### 3.3. Predictive nomogram
Based on the univariate and multivariate cox regression results, the parameters mentioned above were integrated to construct a prognostic nomogram for predicting the 1-, 2-, and 3-year OS and CSS (Fig. 1). Every parameter was assigned a corresponding score on a point-graded scale. The 1-, 2-, and 3-year OS and

---

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | $P$                   |
|                                 |                     |                      |
| Age                              | Reference           |                       |
| 20–59                            | 2.669 (1.424–5.003) | .002                 |
| 60–90                            | 2.572 (1.319–5.017) | .006                 |
| Race                             | Reference           |                       |
| Black                            | 0.631 (0.235–1.697) | .362                 |
| White                            | 1.242 (0.609–2.533) | .552                 |
| Sex                              | Reference           |                       |
| Female                           | 1.474 (0.901–2.411) | .123                 |
| Male                             | 1.474 (0.901–2.411) | .123                 |
| Histological subtype             | Reference           |                       |
| Papillary                        |                     |                       |
| Follicular                       | 0.757 (0.363–1.577) | .457                 |
| Anaplastic                       | 20.915 (9.492–43.999) | <.001 |
| Medullary                        | 3.121 (1.406–6.917) | .005                 |
| Grade                            | Reference           |                       |
| Low (I, II)                      | 8.618 (3.907–18.579) | <.001 |
| High (III, IV)                   | 3.897 (1.426–10.645) | .008 |
| Unknown                          | 1.705 (0.801–3.631) | .166                 |
| Laterality                       | Reference           |                       |
| Bilateral                        | 5.685 (0.165–15.566) | .685 |
| N stage                          | Reference           |                       |
| T1–2                             | 2.373 (1.239–4.545) | .009                 |
| T3–4                             | 2.373 (1.239–4.545) | .009                 |
| Radiotherapy                     | Reference           |                       |
| Yes                              | 0.29 (0.176–0.477) | <.001                |
| No                               | 0.492 (0.274–0.882) | .017                 |
| Surgery                          | Reference           |                       |
| Yes                              | 0.198 (0.116–0.337) | <.001                |
| No/unknown                       | 5.782 (3.367–9.931) | <.001                |
| Chemotherapy                     | Reference           |                       |
| Yes                              | 2.347 (0.571–9.645) | .237                 |
| No/unknown                       | 1.027 (0.321–3.282) | .964                 |
| Brain metastasis                 | Reference           |                       |
| Yes                              | 1.202 (0.165–8.751) | .856                 |
| No                               | 3.681 (0.355–38.374) | .276                 |
| Unknown                          | 4.599 (2.548–8.304) | <.001                |
| Lung metastasis                  | Reference           |                       |
| Yes                              | 2.307 (1.269–4.195) | .006                 |
| No/historical stage              | Reference           |                       |
| Yes                              | 0.62 (0.083–4.613) | .641                 |
| No                               | 3.671 (2.195–6.141) | <.001                |
| Liver metastasis                 | Reference           |                       |
| Yes                              | 1.951 (1.895–5.24)  | <.001                |
| No                               | 0.62 (0.083–4.613) | .641                 |
| Lung metastasis                  | Reference           |                       |
| Yes                              | 3.671 (2.195–6.141) | <.001                |
| No                               | 2.307 (1.269–4.195) | .006                 |

---
CSS of TCBM patients could be predicted by adding up these scores for a total. Remarkably, this upgraded nomogram provided a visual impact; the bigger the block area of each indicator, the more number of patients the indicator corresponded to.

### 3.4. Validation of the nomogram

The nomogram had high C-index, 0.82 (95% CI: 0.767–0.873) for OS and 0.852 (95% CI: 0.801–0.903) for CSS, which indicated that the models had a high accuracy prediction. The calibration curves demonstrated excellent consistency between the predicted result and the actual survival of the TCBM patients (Figs. 2 and 3). ROC analysis showed that the AUC for OS at 1-, 2-, and 3-year in the training cohort was 0.885, 0.875, and 0.868 and 0.810, 0.729, and 0.729 in the validation cohort, respectively (Fig. 4). The AUC for CSS at the same time points stood at 0.913, 0.909, and 0.909 in the training cohort and 0.840, 0.827, and 0.827 in the validation cohort (Fig. 5). Also, the DCA curve indicated that this nomogram had good clinical utility in predicting the OS and CSS in patients with TCBM (Figs. 6 and 7). Kaplan–Meier survival analysis was also performed in the training and the validation cohorts (Fig. 8), which showed that patients with high-risk scores had shorter OS and CSS than those with low-risk scores.

### 3.5. Comparison of the prediction accuracy between nomogram and single independent prognostic factor

AS shown in Figures 4 and 5, the AUC of every independent prognostic factor for OS and CSS was significantly lower than that of the nomogram, implying that the prediction accuracy of the nomogram for the 1-, 2-, and 3-years OS and CSS was better.
Figure 2. Calibration curves. Calibration curves of the nomogram for the 1- (A), 2- (B), and 3-year (C) OS prediction of the training cohort, calibration curves of the nomogram for the 1- (D), 2- (E), and 3-year (F) OS prediction of the validation cohort.

Figure 3. Calibration curves. The calibration curves of the nomogram for the 1- (A), 2- (B), and 3-year (C) CSS prediction of the training cohort, calibration curves of the nomogram for the 1- (D), 2- (E), and 3-year (F) CSS prediction of the validation cohort.
Figure 4. ROC curves. ROC curves for predicting 1- (A), 2- (B), and 3-year (B) OS in the training cohort; ROC curves for predicting 1- (D), 2- (E), and 3-year (F) OS in the validation cohort.

Figure 5. ROC curves. ROC curves for predicting 1- (A), 2- (B), and 3-year (B) CSS in the training cohort; ROC curves for predicting 1- (D), 2- (E), and 3-year (F) CSS in the validation cohort.
Figure 6. Decision curve analysis (DCA). DCA of the nomogram for predicting the 1- (A), 2- (B), and 3-year (C) OS in the training cohort, and the 1- (D), 2- (E), and 3-year (F) OS in the validation cohort.

Figure 7. Decision curve analysis (DCA). DCA of the nomogram for predicting the 1- (A), 2- (B), and 3-year (C) CSS in the training cohort, and the 1- (D), 2- (E), and 3-year (F) CSS in the validation cohort.
4. Discussion

Given the treatability and excellent survival rate in patients of TC, an opinion that it is a relatively “good cancer” has pervaded the medical community. However, TCBM still carries an inferior prognosis with the 10-year survival rate varying from 13% to 21%. A large-scale study evaluating the long-term prognosis evaluation of 444 TC patients with DM suggested that the 10-year OS of patients with BM was significantly lower than that of patients with lung metastasis (25% vs 63%). Similar results were reported in other studies. Therefore, it appears that accurate prediction of survival rates for TCBM patients of utmost significance for effective clinical management and medical decision-making.

The use of nomograms has become increasingly popular and important in personalized cancer prediction, helping clinicians optimize the therapeutic options for patients in accordance with the specific individual variables. Predictive nomograms for the survival prediction of some malignancies have been reported. The merit of nomogram lies in simplifying complex statistical predictive models involving a large number of factors to a single brief numerical estimation model, predicting the probability of a clinical outcome. In our model, each independent risk factor included in this model was given a weighted point to evaluate the effect of this factor on prognosis. It has a distinctive advantage of being a tailor-made survival prediction model as compared to the conventional TNM staging system. Nomograms have been previously developed for the survival prediction in patients with TC. Some studies focusing on the evaluation of prognostic factors in TCBM patients have also been reported. However, there is an overall lack of a nomogram predicting the OS and CSS for TCBM patients. In the present study, for this reason, we identified the independent risk factors for OS and CSS for TCBM patients, and further established a nomogram for respectively predicting the 1-, 2-, and 3-year OS and CSS in those patients. The developed nomograms performed excellently in prediction of survival rate as supported by C-index, calibration curves, ROC curves, and DCA. This predictive model highlights the relative contribution of the various independent variables associated with clinical outcome so that it may be conveniently and directly used to predict the survival rate in TCBM patients, informing the

Figure 8. Kaplan-Meier survival analysis. Patients with a higher risk score demonstrated a worse prognosis than those with a low risk score in the training cohort for OS of TCBM patients (A), for CSS of TCBM patients (C), and validation cohort for OS of TCBM patients (B), for CSS of TCBM patients (D).
patients of individuals benefits of specific treatments, hence optimizing clinical decision-making. Furthermore, some other advantages of this study are as follows: first, it is a longitudinal population-based study with the relatively large sample size that included all types of TC. The results of this study, hence, have a good representative value in providing clinical guidance. Secondly, we believe that this nomogram is of clinical interest and practical utility because the identified independent prognostic predictors are easily accessible and may be used in the daily treatment planning. In addition, another improvement of this nomogram is that the discrimination of nomogram was confirmed to be better than any of those predicted by the independent risk factors separately, which once again showed the significance of a comprehensive predictive model. In our study, age, grade, histological subtype, liver metastasis, and radiotherapy were found to be the independent risk factors for OS of TCBM patients. The independent risk factors of CSS included those above along with were not only the above variables, but also included tumor size and lung metastasis. Interestingly, although previous reports have considered the race of patients as a closely related factor for predicting long-term outcome of TC, it was not identified as an independent prognostic factor in our prognosis analysis. This confirmed the necessity of determining more precisely applicable population characteristics in the prognostic evaluation of these patients. There are some disputes on the correlation between age and prognosis of TCBM. Several lines of evidence suggested that the TCBM patients with older age were associated with worse prognosis. However, some scholars hold the opposite viewpoint that age did not significantly affect the prognosis. In our series, age was identified as an independent risk factor for determining the OS and CSS. We also determined the optimum cutoff value of age for both OS and CSS (58 and 59 years, respectively) by using the X-tile program. In our study, patients with age ≥59 years were found to have inferior OS and CSS. The complexity associated with various other diseases, low physical fitness as well as low tolerance toward cancer treatment methods were identified as the main reasons of an advanced age patients facing increased risk. Similar to other malignancies, the grade was also an independent predictor for TCBM. The result of our study suggested that the risk of death in TCBM patients with high-level grade (III, IV) was significantly higher than that in patients with low-level grade (I, II). High grade tumors also showed more extensive tumor invasion and the more complications impairing the treatment efficacy. According to Wu Karl et al., the survival of TCBM patients was significantly longer in patients with papillary and follicular histology than in whose with anaplastic and medullary cancers. Our predictive model also supported this conclusion. Anaplastic histology occupied the most significant weight point of all histological subtypes. Also, TCBM patients having a tumor size ≥73 mm indicated poor prognosis. We analyzed that larger tumor size corresponded to greater infiltration range and higher level grade, increasing the overall complexity and risk of surgical resection. In the clinical practice, more metastasis represents an unfavorable prognosis. In a significant study, pointed out that 3-year OS of TCBM patients reporting other metastatic sites was 13% less than that of those with only BM. However, the previous studies did not specify which combined metastatic sites associated with a lower survival rate. Our study identified liver metastasis as an independent risk factor, speculating that hepatic failure caused by liver involvement might be a possible cause of death for some patients with TCBM. It is noteworthy that treatment strategy relies on clinicians personal judgment and experience gained from training and practice in the absence of accurate survival predictive model. As is common knowledge, the effectiveness of conventional external beam radiotherapy in BM is widely accepted. Radiotherapy played a vital role in predicting the prognosis of TCBM patients in our model. There are several lines of evidence suggesting that stereotactic radiotherapy following conventional radiation for TCBM demonstrates high local control rates of ~80% to 90%, Furthermore. It is widely accepted that radioactive iodine (RAI) therapy was an ideal specific treatment for patients with TC. Related research confirmed that the application of high-dose RAI could considerably benefit the patients by improving the prognosis in patients with metastatic DTC. The previous studies were consistent with our results, all of which highlighted the immense significance of radiotherapy in predicting the prognosis of TCBM patients. Regrettfully, no nomogram can assess the impact of a predictor in prognosis with 100% accuracy. Our predictive model also has some limitations. First, since the design of the present study was a clinical retrospective study, selection bias was unavoidable. Second, patients included in our study were diagnosed between 2010 and 2016, leading to a relatively insufficient time frame. This was because the SEER database had recorded the metastatic sites from 2010 onward. We think that a more extended time frame with a larger sample size might help to further enhance the credibility and persuasiveness of the model prediction. Third, the nomogram only provides a relative reference for clinicians due to limitation in the collected variables and data. For example, the severity of other organ metastases is not recorded in the SEER database. It is imperative to remember that the final treatment strategy relies mostly on clinicians personal judgment and experience in the absence of an accurate survival prediction model. Ideally, more complex clinical factors that doctors face in their daily is an integral element of decision making and prognostic evaluation. Nevertheless, these models do have the potential to revolutionize the practice of personalized medicine.

5. Conclusion

In conclusion, our model shows that TCBM patients with age ≥59 years, advanced grade, primary tumor size ≥73 mm, lung metastasis and liver metastasis have a poor prognosis. This study have successfully constructed and validated a visual nomogram for predicting the 1-, 2-, and 3-year OS and CSS of TCBM patients, and could be used as an assistant prediction tool in clinical practice. The same needs to be validated in larger cohorts.

Acknowledgments

We are thankful for the contribution of the SEER database and the 18 registries supplying cancer research information, and thank all colleagues involved in the study for their contributions.

Author contributions

Conceptualization: You-Xin Song, Cheng-Liang Zhao, Yue-Xin Tong.
Data curation: Yue-Xin Tong, Zhang-Heng Huang, Chang-Xing Chi.
Formal analysis: Chuan Hu, Meng Lv, Peng-Fei Li.
Methodology: Yue-Xin Tong.

Supervision: You-Xin Song, Cheng-Liang Zhao.

Writing – original draft: Yue-Xin Tong.

Writing – review & editing: You-Xin Song, Cheng-Liang Zhao, Yue-Xin Tong.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.

[2] Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008;15:37–49.

[3] Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297–306.

[4] Durante C, Haddly N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9.

[5] Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 2007;14:730–8.

[6] Huang IC, Chou FF, Liu RT, et al. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012;76:439–47.

[7] Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.

[8] Londero SC, Krogdahl A, Bastholt L, et al. Papillary thyroid carcinoma in Denmark, 1996–2006: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid 2015;25:78–84.

[9] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–33.

[10] See A, Iyer NG, Tan NC, et al. Distant metastasis as the sole initial manifestation of well-differentiated thyroid carcinoma. Eur Arch Otorhinolaryngol 2017;274:2877–82.

[11] Matta-Coelho C, Simões-Pereira J, Vilar H, et al. Bone metastases from thyroid carcinoma of follicular origin: a single institutional experience. Eur Thyroid J 2019;8:96–101.

[12] Farroki F, Leung V, Tala H, et al. Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 2012;97:2433–9.

[13] Suh S, Kim YH, Goh TS, et al. Outcome prediction with the revised American joint committee on cancer staging system and American thyroid association guidelines for thyroid cancer. Endocrine 2017;58:495–502.

[14] Zhi Z, Wu Y, Hu L, et al. Assessment of the prognostic value and NLR changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma. Int J Clin Oncol 2020;25:59–66.

[15] Choi YM, Kim WG, Kwon H, et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2016;175:165–72.

[16] Nakayama R, Horsuchi K, Sasa M, et al. Clinical outcome after bone metastases (BM) surgery in patients with differentiated thyroid cancer (DTC): a retrospective study of 40 cases. Jap J Clin Oncol 2014;44:918–25.

[17] Wu K, Hou SM, Huang TS, et al. Thyroid carcinoma with bone metastases: a prognostic factor study. Clin Med Oncol 2008;2:129–34.

[18] Ishigaki T, Uruton T, Sugino K, et al. Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer. J Radiat Res 2019;60:831–6.

[19] Lin Z, Yan S, Zhang J, et al. A nomogram for distinction and potential prediction of liver metastasis in breast cancer patients. J Cancer 2018;9:2098–106.

[20] Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252–9.

[21] Silva TB, Oliveira CZ, Faria EF, et al. Development and validation of a nomogram to estimate the risk of prostate cancer in Brazil. Anticancer Res 2015;35:2881–6.

[22] Randell RW, Bushman NM, Orme J, et al. Papillary thyroid cancer: the good and bad of the “Good Cancer”. Thyroid 2017;27:902–7.

[23] Bernier MO, Lemoirdt L, Hung C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001;86:1568–73.

[24] Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261–8.

[25] Sampson E, Brierley JD, Le IW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110:1451–6.

[26] Chen S, Chen S, Lian G, et al. Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. Cancer Med 2020;9:2971–80.

[27] Xiong Z, Deng G, Huang X, et al. Score for the survival probability in metastasis breast cancer: a nomogram-based risk assessment model. Cancer Res Treatment 2018;50:1260–9.

[28] Wo Y, Yang H, Zhang Y, et al. Development and external validation of a nomogram for predicting survival in patients with stage IA non-small cell lung cancer ≤2cm undergoing sublobectomy. Front Oncol 2019;9:1385.

[29] Zheng XQ, Huang JP, Lin JL, et al. Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study. Transl Lung Cancer Res 2019;8:367–79.

[30] Adam MA, Thomas S, Roman SA, et al. Rethinking the current American Joint Committee on cancer TNM staging system for medullary thyroid carcinoma. JAMA Surg 2017;152:869–76.

[31] Wang K, Xu J, Li S, et al. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer among patients with papillary thyroid microcarcinoma. Cancer Med 2019;8:877–85.

[32] Wen Q, Yu Y, Yang J, et al. Development and validation of a nomogram for predicting survival in patients with thyroid cancer. Med Sci Monit 2019;25:5361–71.

[33] Tang J, Kong D, Cui Q, et al. Racial disparities of differentiated thyroid carcinoma: clinical characteristics, treatments, and long-term outcomes. World J Surg Oncol 2018;16:45.

[34] Lin JD, Lin SF, Chen ST, et al. Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastases. PLoS One 2017;12:e0173354.

[35] Kondrakiuc JD, Rice SL, Zhou X, et al. Thyroid cancer bone metastasis: survival and genomics characteristics of a large tertiary care cohort. Clin Nuclear Med 2019;44:465c–71.

[36] Hu P, Bui J, Liu M, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer 2020;23:591–9.

[37] Huang R, Sun Z, Zheng H, et al. Identifying the prognostic factors and predicting the survival probability in patients with non-metastatic chondrosarcoma from the SEER database. Orthop Surg 2019;11:801–10.

[38] Wang LY, Palmer FL, Nixon IJ, et al. Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 2014;24:1594–9.

[39] Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to radioiodine therapy and prognostic factors. JAMA 2013;310:1819–26.

[40] Song HJ, Qiu ZL, Shen CT, et al. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol 2015;173:399–408.

[41] Riel H, Katayama S, Bruckner T, et al. High-dose single-fraction IMRT versus fractionated external beam radiotherapy for patients with spinal bone metastases: study protocol for a randomized controlled trial. Trials 2015;16:264.

[42] Gersztenc P, Mende E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine 2009;34:878–92.

[43] Bernstein MB, Chang EL, Amnu i B, et al. Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase II/III trials. Thyroid 2016;26:1269–75.

[44] Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 2006;30:1088–95.

[45] Mihalovic J, Stefanovic I, Malasevic M, et al. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases. Thyroid 2009;19:227–32.